The study noted that increased inhibition of these cascades may correlate with decreased inflammatory markers.
Analysis involves cellular pathways related to LUBAC and its impact on mediators like IL-1β in fibrosis.
Findings support the use of LUBAC as a potential therapeutic target, highlighting its role in managing pulmonary fibrosis.
Resumen
LUBAC is involved in PF and inhibited by ISOF. In addition, ISOF may ameliorate PF by inhibiting the LUBAC/GSDMD/IL-1β cascades. Accordingly, LUBAC may be a potential therapeutic target for PF.